| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Collaboration revenue | - | - | 109,164 | 791 |
| Research and development | 22,526 | 26,859 | 26,580 | 27,228 |
| General and administrative | 6,835 | 7,805 | 8,408 | 8,352 |
| Impairment of long-lived assets | 6,763 | - | - | - |
| Total operating expenses | 36,124 | 34,664 | 34,988 | 35,580 |
| Income (loss) from operations | -36,124 | -34,664 | 74,176 | -34,789 |
| Interest income | 1,605 | 2,010 | 2,422 | 3,305 |
| Other income | 97 | 113 | -38 | 250 |
| Total other income | 1,702 | 2,123 | 2,384 | 3,555 |
| Income (loss) before provision for income taxes | -34,422 | -32,541 | 76,560 | -31,234 |
| Income tax expense (benefit) | - | - | - | -8 |
| Net income (loss) | -34,422 | -32,541 | 76,560 | -31,226 |
| Unrealized gain (loss) on investments | -19 | -222 | -19 | 1,075 |
| Other comprehensive income (loss), foreign currency transaction and translation adjustment, net of tax, portion attributable to parent | - | - | - | -8 |
| Comprehensive income (loss) | -34,441 | -32,763 | 76,541 | -30,159 |
| Earnings per share, basic | -0.4 | -0.38 | 0.89 | -0.37 |
| Earnings per share, diluted | -0.4 | -0.38 | 0.89 | -0.37 |
| Weighted average number of shares outstanding, basic | 86,464,066 | 86,238,084 | 86,021,188 | 84,704,352 |
| Weighted average number of shares outstanding, diluted | 86,464,066 | 86,238,084 | 86,098,619 | 84,704,352 |
Century Therapeutics, Inc. (IPSC)
Century Therapeutics, Inc. (IPSC)